• | home
  • | corporate
  • | investors
  • | products
  • | clinical trials
  • | partnering
  • | contact
TSX: HBP - NYSE Amex: HBP - Frankfurt: HBP

  • | Product Overview
  • | Topical Interferon Alpha-2b
  • | DOS47
    • | L-DOS47
  • | Orthovisc®
  • | Monovisc®
  • | Normacol™
  • | Imunovir™
  • | Klean-Prep™

Monovisc®

Through Helix’s drug distribution division Rivex Pharma, the product Monovisc™ is distributed in Canada based on an agreement with Anika Therapeutics Inc. Monovisc™ (sodium hyaluronate) reduces joint pain and improves joint mobility providing significant relief from the pain of osteoarthritis (OA) of the knee and has been especially formulated for single-injection procedures. Monovisc™ supplements the synovial fluid to naturally augment lubrication, cushioning and offer protection to the arthritic knee joint.

Monovisc™ is injected using a simple procedure called viscsupplementation. The procedure is performed by an orthopaedic surgeon, rheumatologist, or other qualified health professional. The doctor prepares the patient's knee with a local anesthetic, then injects Monovisc™ directly into the knee joint where it combines with the synovial fluid. Monovisc™ acts only in the knee joints, so it will not interfere with any other medications the patient is taking 1.

For many patients, relief of osteoarthritic discomfort begins immediately. Full benefit is achieved after one simple treatment.

Significant pain reduction from OA of the knee can last up to 6 months2. Patients will enjoy enhanced joint mobility and joint protection. Patients will be able to resume many of the activities they once enjoyed.

Monovisc™ is available through a doctor.
Monovisc™ is a registered trademark of Anika Therapeutics, Inc.

1 Stitik TP, Viscosupplementation for Osteoarthritis, Phys Med Rehab 2001; 15: 117 – 145

2 Brandt KD, Smith GN & Simon LS, Intra Articular Injection of Hyaluronan in the Treatment of Knee Osteoarthritis; Arthritis & Rheumatism, 2000,43: 1192 – 1203

 

For more information about Rivex Pharma, please go to http://www.rivexpharma.com or call 888.922.8472 (VISC). 

Helix distributes pharmaceutical and medical products in Canada to assist with the treatment and/or prevention of disease. The Corporation's products are intended only for use in countries in which they have received regulatory approval, under the direction of qualified health care professionals approved by government agencies in such countries.

Material on this website regarding the Corporation's products is provided for information purposes only. Inclusion of products and information on this site does not imply any official medical advice, recommendation or warranty. Information provided is not a substitute for the advice of an appropriate health professional. This website can be accessed from countries around the world and may contain references to the Corporation's products and programs that have not been granted regulatory approval in your country.

Please consult your health professional for detailed information regarding the Corporation's products
 

 



  • | home
  • | site map
  • | privacy
  • | terms of use / disclaimers
  • | polski
  • | login
© Helix BioPharma Corp.